Background: Hepatitis C virus (HCV) is a leading cause of chronic hepatitis in dialysis patients. The diagnosis of HCV infection in these patients is predominantly based on laboratory tests because of the specifi city of the clinical course of the disease. Aim: The present prospective study aimed at determining very accurately the prevalence rate of HCV infection in patients on dialysis by simultaneously testing them for anti-HCV and for HCV RNA levels. Materials and methods: For the present cross-sectional longitudinal study we recruited and followed up 93 patients from St George University Hospital Hemodialysis Unit between July 2013 and December 2014. All patients were tested for anti-HCV and HCV RNA. The anti-HCV negative patients were tested for anti-HCV and HCV RNA at least twice at intervals of 6 months or more (up to 12 months). Anti-HCV antibodies were identifi ed using a third generation ELISA assay. Commercial kits for real-time polymerase chain reaction (RT-PCR) were used to detect HCV RNA in the plasma and mononuclear cells. Aminotransferase and gammaglutamyl transpeptidase levels were studied to fi nd if liver infl ammation was present. Results: The total seroprevalence in 68 patients was 20.6% (14) . Of these, 10 patients were viremic (HCV RNA+/anti-HCV+), and 4 patients (5.9%) had discordant results (anti-HCV+/HCV RNA-). Acute hepatitis was detected in one patient. Duration of dialysis in HCV viremic patients was longer than that in aviremic patients (p=0.005).
Conclusions:
The present study suggests that HCV infection in dialysis patients can be diagnosed more accurately if these patients are tested using two diagnostic methods -a serological test and a biomolecular assay. Further studies with larger sample size may prove the feasibility of such approach for all dialysis patients in this country.
BACKGROUND
Hepatitis C virus (HCV) is the major culprit causing chronic hepatitis in patients with terminal chronic kidney disease.
Improved dialysis procedures, extensive use of erythropoietin, donor blood screening using more rigorous methods, and strict adherence to standard precautionary measures have reduced HCV infection occurrence rate in dialysis patients but sadly fell short of eliminating the disease among them. At present, the main mode of HCV infection transmission is nosocomial. 1 HCV prevalence varies considerably for the different hemodialysis centres throughout the world -it is very low in the developed countries, especially in Germany (6.1%) and the United Kingdom (3.9%), but it is substantially high in the Middle East countries (Kuwait 71%). [2] [3] [4] HCV infection in dialysis patients tends to run an asymptomatic course with mild changes in the laboratory and morphology parameters. 5, 6 Hence the importance of laboratory studies for patients with HCV infection. Routine laboratory diagnosis of HCV infection is based on the specifi c antibodies identifi ed by an immunoenzyme assay (ELISA). All anti-HCV positive results have to be verifi ed by detecting HCV RNA levels (viral load) in blood, commonly using the polymerase chain reaction (PCR) technique. The quantitative RT-PCR-based assay is among the most highly sensitive tests available with a very low detection limit of HCV RNA -10-50 IU/ml. 7 That is the reason why most researchers recommend that a combination of ELISA and PCR be used in such cases as the most highly sensitive diagnostic approach to HCV infection in dialysis patients. 8, 9 Early diagnosis of this condition has more than just epidemiological signifi cance. Early diagnosis is crucial when it comes to choosing the therapy for HCV-infected candidates for kidney transplantation. Unlike the patients not receiving pretransplantation HCV therapy, those patients treated for HCV prior to transplantation develop very rarely posttransplantation diabetes and glomerulonephritis of the graft. [10] [11] [12] Lately, a special clinical entity has been reported -occult hepatitis C virus infection. The viruses in this form of the disease are detected in the peripheral blood mononuclear cells (PBMCs) and/ or in hepatocytes but not in the blood. 13 There is, however, quite scanty evidence for this form of the disease in hemodialysis patients. 14 There are only few reports of HCV infection in hemodialysis patients in Bulgaria. 15, 16 In 2004, 25.2% of all dialysis patients in Bulgaria were anti-HCV(+) while in the following years the seropositivity rate fell down to 11% in 2009 and to 9.6% in 2012. 17, 18 In Bulgaria, screening dialysis patients is routinely conducted using serological tests, with biomolecular assays being used only in single cases.
AIM
The present prospective study aimed at fi nding the prevalence of HCV infection in hemodialysis patients by testing patients for both the anti-HCV and HCV RNA levels.
MATERIALS AND METHODS

PATIENTS (STUDY DESIGN)
The present cross-sectional study included 93 patients recruited from the Hemodialysis Unit in St George University Hospital, where they were treated between July 2013 and December 2014. Of these, 17 (68) patients were included in a 2007 cross-sectional study.
Inclusion criteria: patients were eligible for registry enrolment if they were on hemodialysis for end-stage chronic renal failure, no younger than 18 years, and had given a written informed consent for participation. Patients on peritoneal dialysis were excluded from the study.
The participants were registered in the study with their demographic and clinical characteristics -sex, age, ethnic group, duration of dialysis, diagnosis of the disease that caused the end-stage chronic renal failure, number of blood transfusions, and previous kidney transplantation.
At baseline, immediately after inclusion into the study, these patients were tested for anti-HCV and HCV RNA. Those that tested positive were retested using another blood sample. In the second phase of the study, the anti-HCV seronegative patients were followed up clinically and tested for anti-HCV and HCV RNA at least twice at an interval of 6 and more than 6 months (up to 12 months).
Plasma and sera were extracted from the blood samples collected from every patient prior to dialysis. The sera were divided into aliquots and used for biochemical and serological tests while the plasma was stored at -80°C until tested for HCV RNA.
To exclude fl uctuating viremia, the patients positive for anti-HCV but negative for HCV RNA were retested two more times for HCV RNA.
The patients who were serum HCV RNA negative at two tests were retested for HCV RNA in the PBMCs to detect occult HCV infection, regardless of whether or not they had anti-HCV antibodies. For this purpose serum was separated from blood immediately after taking the blood sample, stored frozen, and transported to the Laboratory of Molecular Diagnostics of Liver Diseases in St Ivan Rilski University Hospital, Sofi a. 
Detection of HCV RNA in plasma and in peripheral blood mononuclear cells (PBMCs)
Quantitative assessment of plasma HCV RNA was performed using Bosphore ® HCV Quantifi cation kit v1, which uses a RT-PCR assay with detection limit of 25 IU/ml (Anatolia Geneworks, CE, IVD). For PBMCs -after separation of the cells to the initial quantity of about 5.10 6 and isolation of the common RNA, we used the HCV LC RT-PCR method that can be used with LightCycler 1.5 diagnostic instrument (Roche, Switzerland) (Abe M et al.) with detection limit of 27 genomic copies (about 9 IU/ml). Virus genotyping was performed using the same method (Abe M et al.). The molecular and biological studies were performed in the Laboratory of Molecular Diagnostics of Liver Diseases in St Ivan Rilski University Hospital, Sofi a.
BIOCHEMICAL STUDIES Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyl transpeptidase (GGT) were identifi ed by the Central Clinical Laboratory of St George University Hospital, Plovdiv using common automated spectrophotometric methods. The tests were done at intervals of 6 months and if needed. DIALYSIS PROCEDURE Patients were dialyzed for 4 hours thrice weekly. The anti-HCV positive patients were given dialysis in dedicated rooms. The protocol followed in the study was in accordance with the ethical principles of the Declaration of Helsinki and approved by the Ethics Committee of the Medical University in Plovdiv. All participants gave their written informed consent to be entered into the study. STATISTICAL ANALYSIS χ 2 was used to fi nd the relationship between the qualitative variables; Mann-Whitney U test was used to fi nd the relationship between the quantitative variables. A value of p < 0.05 was considered statistically signifi cant. The analysis was performed using SPSS v. 16 .0.
RESULTS
The inclusion criteria were met by 68 patients. All the other patients dropped out of the study because of either a lethal outcome or a transfer to another dialysis centre. At baseline 13 patients were anti-HCV positive with 10 of these HCV RNA positive, that is, they were viremic. Another four were HCV RNA negative -they had discordant results (anti-HCV positive / HCV RNA negative). Evidence of acute HCV hepatitis was found in one of the ten viremic patients. He was HCV RNA positive and anti-HCV negative at baseline but 3 months later we detected seroconversion and intensifi cation of viremia. The same patient had negative HCV markers in 2007. Phylogenetic analysis was not performed for logistic reasons.
There were a total of 14 (20.6%) anti-HCV positive patients, 10 (14.7%) viremic patients and 4 (5.9%) aviremic patients. Table 2 presents the HCV markers of 68 patients. HCV genotype 1 was identifi ed in the ten viremic patients.
Three of the viremic patients were found positive in 2007 -these included a patient placed again on dialysis after rejection of the transplanted kidney. Another patient with fl uctuating levels of viremia was found to have no evidence of HCV RNA at the fi rst test and then the patient's second test found the HCV RNA level to be 1950 IU/ml. One patient was found to have low level viremia, which was not detected in the subsequent two tests for HCV RNA. Such a result was considered false positive.
Thiry-seven patients were tested for HCV RNA in the PBMCs and none were found to have any evidence of occult HCV hepatitis.
The four anti-HCV positive / HCV RNA negative patients were retested for anti-HCV and HCV RNA Comparing the characteristics of viremic and aviremic patients we found that the viremic patients had longer duration of dialysis (p=0.005). Also the mean ALT (p=0.015), AST (р=0.007) and GGT (р=0.012) were higher for the viremic patients yet were within the reference range ( Table 3) . DISCUSSION This is the fi rst prospective study in Bulgaria in which patients on dialysis have been tested simultaneously for anti-HCV and HCV RNA levels. We found 10 patients with viremia (14.6% prevalence) and 1 patient with acute hepatitis (0.015%). In another four patients (0.6%), the only HCV marker was anti-HCV positive antibodies. If these patients had been tested only serologically, which is the routine practice in Bulgaria for dialysis patients, they would have been misdiagnosed as infected.
The HCV prevalence we found in this study was high; it was 10 times as high as that in the general Bulgarian population. 19 It was also higher than the prevalence for the entire dialysis population over the last years: 11% for 2009 and 9.6% for 2012. We used two diagnostic methods -serological tests and biomolecular assays, and tested every patient with these two methods at least twice. This was done to reduce to a minimum the occurrence of false positive or false negative results and to assess very accurately the prevalence rate.
The characteristics of the viremic patients were not much different from the ones available up to now: they were with asymptomatic course and negligible It is of particular signifi cance that many researchers have reported lower serum levels of aminotransferases in dialysis patients than those in individuals with normal renal function. Although diffi cult to account for, this fi nding is believed to be probably related to vitamin B6 defi ciency and to some uremic toxins. For this reason new lower reference values have been suggested: 18 IU/l for AST and 16 IU/l for ALT. If assessed by these criteria, the enzyme levels are high in most patients. 20 , 21 The levels we found were also higher than the lower reference values -ALT > 16 IU/l and AST > 18 IU/l in 7 (70%) viremic patients.
As found by many researchers, the major risk factors are dialysis duration and the number of blood transfusions; a complementary risk factor is renal transplantation. 22, 23 These factors are interdependent, that is, the longer the treatment the greater the likelihood of more blood transfusion. An independent risk factor for HCV infection in the present study is the duration of dialysis procedure.
A patient with renal transplantation in 1998, 10 years after starting dialysis, presents an interesting case. In 2004, due to transplant rejection, the patient was placed on dialysis again. There was no evidence of any anti-HCV tests for this patients between 1998 and 2004. Screening organ donors for HCV in the European Union countries started in 1994 which makes it highly unlikely for the graft to our patient to have been tested for that. The prevalence of anti-HCV(+) for patients resuming dialysis because of a rejected graft is greater than that of patients just starting dialysis treatment. As suggested by other researchers, the infection in our case is quite likely to have occurred after blood transfusions either due to nosocomial transmission or via the graft. 23 What assays are used to determine HCV can impact the prevalence rate measured. The condition was found to be underdiagnosed back in the early 1990s using the fi rst and second generation of ELISA as a result of the lesser sensitivity of these tests. The currently used third generation ELISA has high sensitivity and specifi city. And yet, some immunodefi cient dialysis patients (such as the diabetics) may remain anti-HCV negative even after they have been infected. 24 Antibodies are however useless in differentiating between current and past infection. The second diagnostic method, the biomolecular method, is a confi rmatory test used to determine the levels of HCV RNA. A number of techniques are available at present and among the most sensitive ones is RT-PCR. The RT-PCR we used has a very low detection level -25 IU/ml. Retesting for HCV RNA allowed us to detect a false positive result in one patient and fl uctuating viremia in another patient.
Using PCR, we were also able to diagnose a case of acute hepatitis C four months before seroconversion. The patient in question had ALT concentrations within normal range but was tested only twice. In acute HCV infection ALT level begins to increase 2 to 8 weeks after exposure. Symptoms usually appear 3-12 weeks (mean 7 weeks) after infection, and anti-HCV become positive either simultaneously or with a little delay. 25 The aminotransferase level might be slightly elevated and transitory. 1 This has a practical signifi cance since for all cases in which there is unexplained ALT increase, even a very slight increase, acute HCV infection should be suspected. It is only by monthly ALT testing of non-infected patients that an ALT increase could be detected. We couldn't fi nd whether this case of acute hepatitis C infection was a result of a nosocomial infection because phylogenetic analysis was not possible.
Occult hepatitis C is a peculiar form of HCV infection with yet unclear signifi cance and a disputed role. In a study of 103 patients on chronic dialysis, Barril et al. 14 found HCV in the PBMCs in 45% of the patients with abnormal liver enzymes. Other researchers have found that HCV does not relapse in patients cured of chronic hepatitis C and with transplanted organs in spite of the long-term immunosuppressive therapy they received. To fi nd the clinical signifi cance and the epidemiologic risk of transmission of occult HCV infection, Baid-Agrawal et al. 26 recommend long-term testing of populations with high incidence.
Four patients with discordant results (anti-HCV positive / HCV RNA negative) are worth a special attention. Their results can be associated with fl uctuating viremia, previous exposure to HCV or could be biologically false positive. The triple HCV RNA negative results for the patients' plasma exclude the fi rst possibility. They are unprotected although they do not carry epidemiological risk. They could also be accounted for by a previous acute hepatitis C infection that resolved spontaneously. Recovery after acute hepatitis C of patients on dialysis is, however, very rare in comparison with the general population. After viruses clear, specifi c antibodies may disappear and persist thus for several years, and could very rarely be found in low concentrations over many years. 27 In these cases, however, HCV RNA is found in PBMCs which we did not fi nd in our study contingent. 28 It is, however, not impossible to fi nd HCV RNA in the liver tissue. To exclude a third possibility, biologically false positive results, it is necessary to have a retest with ELISA, commonly obtained from another manufacturer, using antigens of different immunodominant regions. In cases of biologically false positive results, when one and same sample is tested using a different ELISA assay, the positive result is usually not subjected to testing. This could be due to the great variability of the individual immune response to different antigens in the test kits or different vectors in cloning recombinant proteins. 29, 30 Use of a different ELISA assay as a complementary test after positive sample in screening is introduced in the algorithm for HCV testing of the United Kingdom (National Standard Method VSOP5i5,2005). Such an algorithm is recommended also by CDC (Сenter for Disease Control and Prevention) in 2013. 31 We would like to note some of the limitations of the present study, such as small size of population sample, irregular incomplete liver function tests, no data for HCV status prior to beginning of dialysis. The great turnover of dialysis patients, discarding some due to lethal outcome, a transfer to a different dialysis center and inclusion of new patients make it diffi cult to have a thorough medical documentation. Nevertheless, we found very accurately the HCV status of 68 patients on dialysis -they had a prevalence of 14.7% rather than 20.6% that would have come out if routinely screened with ELISA.
In 2008, the working group KDIGO (Kidney Disease: Improving Global Outcomes) published the fi rst clinical practice guidelines dealing with different aspects of HCV infection in end-stage chronic renal failure patients. It is recommended that the anti-HCV screening for HCV negative patients be done at intervals of 6 to 12 months. For maximum elimination of false positive or false negative results, the screening method is determined dependent upon the prevalence of HCV infection in the respective dialysis center. Serological tests are recommended in low infection prevalence, while nucleic acid amplifi cation tests are to be used in cases with high prevalence of the infection. 10 
CONCLUSION
The results of the present study suggest that a higher accuracy of diagnosing HCV infection in dialysis patients can be achieved if two diagnostic methods -a serological test and a biomolecular assay -are used simultaneously. To see if such approach is feasible for all dialysis patients in this country further studies including a larger sample size are required. 
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